XBIO REPORT

Tag: HIV

September 29, 2026

A Breakthrough in Gene Therapy: Modified HIV Virus Used to Treat Multiple Sclerosis

Harnessing Viral Power for Healing In a fascinating leap for medical science, researchers have utilized a modified version of the HIV virus to address the debilitating effects of Multiple Sclerosis (MS). By stripping the virus of its ability to cause disease, scientists transformed it into a vehicle capable of delivering corrective genetic instructions to the…

Clinical Trial

clinical trials, gene therapy, HIV, Multiple Sclerosis, neurology
August 31, 2026

A New Milestone in HIV Care: FDA Approves Bixlenvo

NASDAQ: $GILD A New Option for HIV Management The landscape of HIV treatment continues to evolve, offering more flexibility for those living with the virus. The FDA has officially approved Bixlenvo, a new medication combining bictegravir and lenacapavir, specifically designed for adults who are already virologically suppressed. Understanding Bixlenvo Bixlenvo is indicated for use in…

FDA Acceptance

$GILD, Antiretroviral Therapy, Bictegravir, Bixlenvo, FDA Approval, HIV
August 28, 2026

A Major Milestone: FDA Approves Tivicay PD for Infants Living with HIV

A New Option for the Youngest Patients ViiV Healthcare has reached a significant milestone in pediatric HIV care. The U.S. Food and Drug Administration (FDA) has officially approved Tivicay PD (dolutegravir), a dispersible tablet formulation designed specifically for infants and children living with HIV who weigh at least 2 kg. Why This Approval Matters Prior…

FDA Acceptance

FDA Approval, HIV, pediatric HIV, Tivicay PD, ViiV Healthcare

Tag: HIV

A Breakthrough in Gene Therapy: Modified HIV Virus Used to Treat Multiple Sclerosis

A New Milestone in HIV Care: FDA Approves Bixlenvo

A Major Milestone: FDA Approves Tivicay PD for Infants Living with HIV